Polyoxometalate-Decorated Gold Nanoparticles Inhibit β-Amyloid Aggregation and Cross the Blood-Brain Barrier in a...

Area of Science:

• Nanotechnology
• Neuroscience
• Biomedical Engineering

Background:

• Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) aggregation, with no effective treatments currently available.
• Inhibiting Aβ aggregation is a primary therapeutic strategy for Alzheimer's disease.
• Developing novel nanotherapeutic systems is crucial for AD treatment.

Purpose of the Study:

• To develop and characterize a novel tri-component nanohybrid system, AuNPs@POM@PEG, for inhibiting Aβ aggregation.
• To evaluate the in vitro efficacy of AuNPs@POM@PEG in reducing Aβ aggregation.
• To assess the cytotoxicity and blood-brain barrier (BBB) permeability of the AuNPs@POM@PEG system for potential Alzheimer's disease nanotherapy.

Main Methods:

• Synthesis of a tri-component nanohybrid system (AuNPs@POM@PEG) using gold nanoparticles (AuNPs), polyoxometalates (POMs), and polyethylene glycol (PEG).
• In vitro assessment of Aβ aggregation inhibition using the developed nanohybrid system.
• Cytotoxicity evaluation on human neurovascular cells.
• Analysis of brain permeability using an in vitro BBB-on-a-chip microphysiological model with 3D human neurovascular co-cultures.

Main Results:

• The AuNPs@POM@PEG system demonstrated significant inhibition of amyloid fibril formation, reducing Aβ aggregation by 75% in vitro.
• The nanohybrid system exhibited no cytotoxicity to human neurovascular cells at concentrations below 2.5 nM.
• The AuNPs@POM@PEG system successfully crossed the brain endothelial barrier in the BBB-on-a-chip model without compromising barrier integrity.

Conclusions:

• The developed AuNPs@POM@PEG nanohybrid system is a stable, non-cytotoxic agent with demonstrated efficacy in inhibiting Aβ aggregation.
• The system possesses the ability to cross the blood-brain barrier, indicating its potential as a nanotherapeutic for Alzheimer's disease.
• Further investigation of AuNPs@POM@PEG is warranted for its development into an effective Alzheimer's disease treatment.